 |
|
Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy
Myung Jin Oh, Heon Ju Lee, Si Hyung Lee
Clin Mol Hepatol. 2013;19(3):288-299. Published online 2013 Sep 30 DOI: https://doi.org/10.3350/cmh.2013.19.3.288
|
|
Citations to this article as recorded by
 Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations
Ming Zhao, Zhi Guo, Ying-Hua Zou, Xiao Li, Zhi-Ping Yan, Min-Shan Chen, Wei-Jun Fan, Hai-Liang Li, Ji-Jin Yang, Xiao-Ming Chen, Lin-Feng Xu, Yue-Wei Zhang, Kang-Shun Zhu, Jun-Hui Sun, Jia-Ping Li, Yong Jin, Hai-Peng Yu, Feng Duan, Bin Xiong, Guo-Wen Yin,
Hepatology International.2024; 18(1): 4. CrossRef Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
Young Eun Ahn, Sang Jun Suh, Hyung Joon Yim, Yeon Seok Seo, Eileen L. Yoon, Tae Hyung Kim, Young Sun Lee, Sun Young Yim, Hae Rim Kim, Seong Hee Kang, Young Kul Jung, Ji Hoon Kim, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun
Gut and Liver.2021; 15(2): 284. CrossRef High-dose versus Low-dose 5-Fluorouracil and Cisplatin Based Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma
Chae-June Lim, Ji-Yun Hong, Yang-Seok Ko, Min-Woo Chung, Chung-Hwan Jun, Sung-Kyu Choi, Sung-Bum Cho
Journal of Liver Cancer.2019; 19(1): 38. CrossRef Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients
Kei Moriya, Tadashi Namisaki, Shinya Sato, Masanori Furukawa, Akitoshi Douhara, Hideto Kawaratani, Kosuke Kaji, Naotaka Shimozato, Yasuhiko Sawada, Soichiro Saikawa, Hiroaki Takaya, Koh Kitagawa, Takemi Akahane, Akira Mitoro, Junichi Yamao, Hitoshi Yoshij
Clinical and Molecular Hepatology.2019; 25(4): 381. CrossRef Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial
Masatoshi Kudo, Kazuomi Ueshima, Yasutaka Chiba, Sadahisa Ogasawara, Shuntaro Obi, Namiki Izumi, Hiroshi Aikata, Hiroaki Nagano, Etsuro Hatano, Yutaka Sasaki, Keisuke Hino, Takashi Kumada, Kazuhide Yamamoto, Yasuharu Imai, Shouta Iwadou, Chikara Ogawa, Ta
Liver Cancer.2019; 8(6): 505. CrossRef Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial
Masatoshi Kudo, Kazuomi Ueshima, Osamu Yokosuka, Sadahisa Ogasawara, Shuntaro Obi, Namiki Izumi, Hiroshi Aikata, Hiroaki Nagano, Etsuro Hatano, Yutaka Sasaki, Keisuke Hino, Takashi Kumada, Kazuhide Yamamoto, Yasuharu Imai, Shouta Iwadou, Chikara Ogawa, Ta
The Lancet Gastroenterology & Hepatology.2018; 3(6): 424. CrossRef Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model
Sibu P. Kuruvilla, Gopinath Tiruchinapally, A. Colleen Crouch, Mohamed E. H. ElSayed, Joan M. Greve, Nicola Amodio
PLOS ONE.2017; 12(8): e0181944. CrossRef Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy
In Rae Cho, Hye Won Lee, Ki Jun Song, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Jinsil Seong, Kwang-Hyub Han, Jun Yong Park
Oncotarget.2017; 8(45): 79914. CrossRef Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review
Kichang Han
World Journal of Gastroenterology.2016; 22(1): 407. CrossRef Neutrophil/lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5‐fluorouracil
Kazuto Tajiri, Kengo Kawai, Masami Minemura, Satoshi Yasumura, Ayumu Hosokawa, Hideto Kawabe, Gakuto Tomizawa, Toshiro Sugiyama
Hepatology Research.2015; 45(7): 755. CrossRef
|